How I treat essential thrombocythemia.

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm.
• ET can lead to vascular events like thrombosis and bleeding, and can transform into myelofibrosis.

Observation:

• Somatic mutations in JAK2, CALR, or MPL are identified in ~90% of ET patients.
• These mutations improve diagnosis and may aid prognostication due to distinct clinical features.
• Vascular event prevention is a primary therapeutic goal in ET management.

Findings:

• Low-dose aspirin and cytoreductive drugs (hydroxyurea, interferon α) are used for vascular event prevention.
• Hydroxyurea is typically for older patients, while interferon α is for younger patients.
• There is a need for disease-modifying drugs to eradicate clonal hematopoiesis and prevent progression.

Implications:

• Genomic profiling aids in personalized prognostication and clinical decision-making for ET.
• Developing novel therapies is crucial for managing ET, especially in younger patients.
• This case-based discussion illustrates current approaches to ET diagnosis and treatment.